Research progress in systemic lupus erythematosus from 2021 to 2022

LI Yong-Zhen; WU Xiao-Chuan

doi:10.7499/j.issn.1008-8830.2302150

PDF(528 KB)

Chinese Journal of Contemporary Pediatrics ›› 2023, Vol. 25 ›› Issue (8) : 785-790. DOI: 10.7499/j.issn.1008-8830.2302150

EXPERT LECTURE

Research progress in systemic lupus erythematosus from 2021 to 2022

LI Yong-Zhen, WU Xiao-Chuan

Author information +

History +

Abstract

Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organ systems, presenting a complex and diverse clinical manifestation. The heterogeneous treatment response and prognosis of SLE pose significant challenges to its diagnosis, classification, and homogeneous treatment. The emergence of new technologies and fields, such as synthetic biology, genomics, and proteomics, has contributed to a deeper exploration of the pathogenesis and biomarkers of SLE, facilitating precision diagnosis and treatment. This review summarizes the latest research data and achievements in SLE for the years 2021-2022, providing an overview and summary of relevant studies conducted in the past two years.

Key words

Systemic lupus erythematosus / Pathogenesis / Diagnosis / Treatment

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

LI Yong-Zhen, WU Xiao-Chuan. Research progress in systemic lupus erythematosus from 2021 to 2022[J]. Chinese Journal of Contemporary Pediatrics. 2023, 25(8): 785-790 https://doi.org/10.7499/j.issn.1008-8830.2302150

References

1 Tian R, Zhang D, Yao X, et al. Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study[J]. Ann Rheum Dis, 2023, 82(3): 351-356. PMID: 36241363. PMCID: PMC9933169. DOI: 10.1136/ard-2022-223035.
2 Levinsky Y, Broide M, Kagan S, et al. Performance of 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in a paediatric population: a multicentre study[J]. Rheumatology (Oxford), 2021, 60(11): 5142-5148. PMID: 33560345. DOI: 10.1093/rheumatology/keab140.
3 Brown GJ, Ca?ete PF, Wang H, et al. TLR7 gain-of-function genetic variation causes human lupus[J]. Nature, 2022, 605(7909): 349-356. PMID: 35477763. PMCID: PMC9095492. DOI: 10.1038/s41586-022-04642-z.
4 Fillatreau S, Manfroi B, D?rner T. Toll-like receptor signalling in B cells during systemic lupus erythematosus[J]. Nat Rev Rheumatol, 2021, 17(2): 98-108. PMID: 33339987. PMCID: PMC7747191. DOI: 10.1038/s41584-020-00544-4.
5 Meng Y, Ma J, Yao C, et al. The NCF1 variant p.R90H aggravates autoimmunity by facilitating the activation of plasmacytoid dendritic cells[J]. J Clin Invest, 2022, 132(16): e153619. PMID: 35788118. PMCID: PMC9374378. DOI: 10.1172/JCI153619.
6 Peng J, Wang Y, Han X, et al. Clinical implications of a new DDX58 pathogenic variant that causes lupus nephritis due to RIG-I hyperactivation[J]. J Am Soc Nephrol, 2023, 34(2): 258-272. PMID: 36261300. DOI: 10.1681/ASN.2022040477.
7 Sandling JK, Pucholt P, Hultin Rosenberg L, et al. Molecular pathways in patients with systemic lupus erythematosus revealed by gene-centred DNA sequencing[J]. Ann Rheum Dis, 2021, 80(1): 109-117. PMID: 33037003. PMCID: PMC7788061. DOI: 10.1136/annrheumdis-2020-218636.
8 Han X, Gu S, Hong SM, et al. Amelioration of autoimmunity in a lupus mouse model by modulation of T-bet-promoted energy metabolism in pathogenic age/autoimmune-associated B cells[J]. Arthritis Rheumatol, 2023, 75(7): 1203-1215. PMID: 36575806. DOI: 10.1002/art.42433.
9 Sosa-Hernández VA, Romero-Ramírez S, Cervantes-Díaz R, et al. CD11c+ T-bet+ CD21hi B cells are negatively associated with renal impairment in systemic lupus erythematosus and act as a marker for nephritis remission[J]. Front Immunol, 2022, 13: 892241. PMID: 35663936. PMCID: PMC9160198. DOI: 10.3389/fimmu.2022.892241.
10 Abraham R, Durkee MS, Ai J, et al. Specific in situ inflammatory states associate with progression to renal failure in lupus nephritis[J]. J Clin Invest, 2022, 132(13): e155350. PMID: 35608910. PMCID: PMC9246394. DOI: 10.1172/JCI155350.
11 Sasaki T, Bracero S, Keegan J, et al. Longitudinal immune cell profiling in patients with early systemic lupus erythematosus[J]. Arthritis Rheumatol, 2022, 74(11): 1808-1821. PMID: 35644031. DOI: 10.1002/art.42248.
12 Zhang M, Johnson-Stephenson TK, Wang W, et al. Mesenchymal stem cell-derived exosome-educated macrophages alleviate systemic lupus erythematosus by promoting efferocytosis and recruitment of IL-17+ regulatory T cell[J]. Stem Cell Res Ther, 2022, 13(1): 484. PMID: 36153633. PMCID: PMC9509559. DOI: 10.1186/s13287-022-03174-7.
13 Bashant KR, Aponte AM, Randazzo D, et al. Proteomic, biomechanical and functional analyses define neutrophil heterogeneity in systemic lupus erythematosus[J]. Ann Rheum Dis, 2021, 80(2): 209-218. PMID: 32988843. PMCID: PMC7855438. DOI: 10.1136/annrheumdis-2020-218338.
14 Furie RA, van Vollenhoven RF, Kalunian K, et al. Trial of anti-BDCA2 antibody litifilimab for systemic lupus erythematosus[J]. N Engl J Med, 2022, 387(10): 894-904. PMID: 36069871. DOI: 10.1056/NEJMoa2118025.
15 Caielli S, Cardenas J, de Jesus AA, et al. Erythroid mitochondrial retention triggers myeloid-dependent type I interferon in human SLE[J]. Cell, 2021, 184(17): 4464-4479.e19. PMID: 34384544. PMCID: PMC8380737. DOI: 10.1016/j.cell.2021.07.021.
16 Fillatreau S. Antibodies against type I IFN: the bad guys self-restrain in systemic lupus erythematosus[J]. Cell Rep Med, 2023, 4(1): 100903. PMID: 36652912. PMCID: PMC9873922. DOI: 10.1016/j.xcrm.2022.100903.
17 Psarras A, Wittmann M, Vital EM. Emerging concepts of type I interferons in SLE pathogenesis and therapy[J]. Nat Rev Rheumatol, 2022, 18(10): 575-590. PMID: 36097207. DOI: 10.1038/s41584-022-00826-z.
18 宋红梅. 儿童风湿病国际相关诊治指南系列解读之一: EULAR-ACR系统性红斑狼疮分类标准解读[J]. 中国实用儿科杂志, 2020, 35(4): 249-252. DOI:10.19538/j.ek2020040601.
19 Rodrigues Fonseca A, Felix Rodrigues MC, Sztajnbok FR, et al. Comparison among ACR1997, SLICC and the new EULAR/ACR classification criteria in childhood-onset systemic lupus erythematosus[J]. Adv Rheumatol, 2019, 59(1): 20. PMID: 31092290. DOI: 10.1186/s42358-019-0062-z.
20 中华医学会儿科学分会肾脏学组. 狼疮性肾炎诊治循证指南（2016）[J]. 中华儿科杂志, 2018, 56(2): 88-94. DOI: 10.3760/cma.j.issn.0578-1310.2018.02.003.
21 张辉, 杨念生, 鲁静, 等. 狼疮肾炎诊疗规范[J]. 中华内科杂志, 2021, 60(9): 784-790. DOI:10.3760/cma.j.cn112138-20210609-00410.
22 Davidson A. Renal mononuclear phagocytes in lupus nephritis[J]. ACR Open Rheumatol, 2021, 3(7): 442-450. PMID: 34060247. PMCID: PMC8280821. DOI: 10.1002/acr2.11269.
23 Jesus D, Larosa M, Henriques C, et al. Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) enables accurate and user-friendly definitions of clinical remission and categories of disease activity[J]. Ann Rheum Dis, 2021, 80(12): 1568-1574. PMID: 34407927. DOI: 10.1136/annrheumdis-2021-220363.
24 Parra Sánchez AR, Voskuyl AE, van Vollenhoven RF. Treat-to-target in systemic lupus erythematosus: advancing towards its implementation[J]. Nat Rev Rheumatol, 2022, 18(3): 146-157. PMID: 35039665. DOI: 10.1038/s41584-021-00739-3.
25 Arnold J, Dass S, Twigg S, et al. Efficacy and safety of obinutuzumab in systemic lupus erythematosus patients with secondary non-response to rituximab[J]. Rheumatology (Oxford), 2022, 61(12): 4905-4909. PMID: 35266512. DOI: 10.1093/rheumatology/keac150.
26 Urowitz MB, Aranow C, Asukai Y, et al. Impact of belimumab on organ damage in systemic lupus erythematosus[J]. Arthritis Care Res (Hoboken), 2022, 74(11): 1822-1828. PMID: 35439360. PMCID: PMC9805003. DOI: 10.1002/acr.24901.
27 Yao X, Ren Y, Zhao Q, et al. Pharmacokinetics analysis based on target-mediated drug distribution for RC18, a novel BLyS/April fusion protein to treat systemic lupus erythematosus and rheumatoid arthritis[J]. Eur J Pharm Sci, 2021, 159: 105704. PMID: 33440243. DOI: 10.1016/j.ejps.2021.105704.
28 Morand E, Pike M, Merrill JT, et al. Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase II, randomized, double-blind, placebo-controlled trial[J]. Arthritis Rheumatol, 2023, 75(2): 242-252. PMID: 36369798. PMCID: PMC10100399. DOI: 10.1002/art.42391.
29 Merrill JT, Werth VP, Furie R, et al. Phase 2 trial of iberdomide in systemic lupus erythematosus[J]. N Engl J Med, 2022, 386(11): 1034-1045. PMID: 35294813. DOI: 10.1056/NEJMoa2106535.
30 Humrich JY, Cacoub P, Rosenzwajg M, et al. Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial[J]. Ann Rheum Dis, 2022, 81(12): 1685-1694. PMID: 35973803. DOI: 10.1136/ard-2022-222501.
31 Li Y, Tang D, Yin L, et al. New insights for regulatory T cell in lupus nephritis[J]. Autoimmun Rev, 2022, 21(8): 103134. PMID: 35690245. DOI: 10.1016/j.autrev.2022.103134.
32 Li Y, Liu H, Yan H, et al. Research advances on targeted-Treg therapies on immune-mediated kidney diseases[J].Autoimmun Rev, 2023, 22(2): 103257. PMID: 36563769. DOI: 10.1016/j.autrev.2022.103257.
33 Furie RA, Morand EF, Bruce IN, et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial[J]. Lancet Rheumatol, 2019, 1(4): e208-e219.
34 Morand EF, Furie R, Tanaka Y, et al. Trial of anifrolumab in active systemic lupus erythematosus[J]. N Engl J Med, 2020, 382(3): 211-221. PMID: 31851795. DOI: 10.1056/NEJMoa1912196.
35 Chatham WW, Furie R, Saxena A, et al. Long-term safety and efficacy of anifrolumab in adults with systemic lupus erythematosus: results of a phase II open-label extension study[J]. Arthritis Rheumatol, 2021, 73(5): 816-825. PMID: 33225631. PMCID: PMC8252065. DOI: 10.1002/art.41598.
36 Rovin BH, Teng YKO, Ginzler EM, et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial[J]. Lancet, 2021, 397(10289): 2070-2080. PMID: 33971155. DOI: 10.1016/S0140-6736(21)00578-X.
37 Hasni SA, Gupta S, Davis M, et al. Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus[J]. Nat Commun, 2021, 12(1): 3391. PMID: 34099646. PMCID: PMC8185103. DOI: 10.1038/s41467-021-23361-z.
38 You H, Zhang G, Wang Q, et al. Successful treatment of arthritis and rash with tofacitinib in systemic lupus erythematosus: the experience from a single centre[J]. Ann Rheum Dis, 2019, 78(10): 1441-1443. PMID: 31005902. DOI: 10.1136/annrheumdis-2019-215455.
39 K?nig N, Fiehn C, Wolf C, et al. Familial chilblain lupus due to a gain-of-function mutation in STING[J]. Ann Rheum Dis, 2017, 76(2): 468-472. PMID: 27566796. DOI: 10.1136/annrheumdis-2016-209841.
40 Lee J, Park Y, Jang SG, et al. Baricitinib attenuates autoimmune phenotype and podocyte injury in a murine model of systemic lupus erythematosus[J]. Front Immunol, 2021, 12: 704526. PMID: 34497607. PMCID: PMC8419414. DOI: 10.3389/fimmu.2021.704526.
41 Nakayamada S, Tanaka Y. Pathological relevance and treatment perspective of JAK targeting in systemic lupus erythematosus[J]. Expert Rev Clin Immunol, 2022, 18(3): 245-252. PMID: 35138987. DOI: 10.1080/1744666X.2022.2040988.
42 Fang T, Li B, Li M, et al. Engineered cell membrane vesicles expressing CD40 alleviate system lupus nephritis by intervening B cell activation[J]. Small Methods, 2023, 7(3): e2200925. PMID: 36605001. DOI: 10.1002/smtd.202200925.
43 Zhao Z, Jiang H, Xu X, et al. Polymeric dexamethasone prodrugs attenuate lupus nephritis in MRL/lpr mice with reduced glucocorticoid toxicity[J]. Nanomedicine, 2022, 44: 102579. PMID: 35768036. PMCID: PMC9427713. DOI: 10.1016/j.nano.2022.102579.
44 Zhang B, Sun J, Yuan Y, et al. Proximity-enabled covalent binding of IL-2 to IL-2Rα selectively activates regulatory T cells and suppresses autoimmunity[J]. Signal Transduct Target Ther, 2023, 8(1): 28. PMID: 36690610. PMCID: PMC9871032. DOI: 10.1038/s41392-022-01208-3.
45 Mougiakakos D, Kr?nke G, V?lkl S, et al. CD19-targeted CAR T cells in refractory systemic lupus erythematosus[J]. N Engl J Med, 2021, 385(6): 567-569. PMID: 34347960. DOI: 10.1056/NEJMc2107725.
46 Mackensen A, Müller F, Mougiakakos D, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus[J]. Nat Med, 2022, 28(10): 2124-2132. PMID: 36109639. DOI: 10.1038/s41591-022-02017-5.